Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6225223 | 0.98 | IDO1 (0.40) | IDO1POLBSMN1; SMN2ASIC3CYP11B1 | |
| SCHEMBL5794794 | 0.76 | IDO1 (0.41) | IDO1POLBSMN1; SMN2ASIC3CYP11B1 | |
| SCHEMBL15826247 | 0.71 | BTK (0.51) | SMN1; SMN2CYP11B1CYP3A4CYP2E1CYP2D6 | |
| SCHEMBL6436382 | 0.69 | NISCH (0.41) | POLBSMN1; SMN2MAPTBTKKMT2A | |
| SCHEMBL64926 | 0.68 | — | — | |
| SCHEMBL5516559 | 0.68 | ALDH1A1 (0.33) | IDO1CYP3A4MAPTALDH1A1FKBP5 | |
| SCHEMBL7500298 | 0.67 | CYP3A4 (0.42) | IDO1POLBSMN1; SMN2ASIC3CYP3A4 | |
| Hydrochloric Acid SCHEMBL311521 | 0.67 | CYP3A4 (0.42) | IDO1POLBSMN1; SMN2ASIC3CYP3A4 | |
| SCHEMBL30945055 | 0.67 | CYP3A4 (0.42) | IDO1POLBSMN1; SMN2ASIC3CYP3A4 | |
| Hydrochloric Acid SCHEMBL310787 | 0.67 | CYP3A4 (0.42) | IDO1POLBSMN1; SMN2ASIC3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | claimed |
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | claimed |
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | claimed |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF | 2011-09-15 | — | — | US | claimed |
| EP-2341906-A2 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | The University of North Carolina At Chapel Hill (US) | 2011-07-13 | — | — | EP | claimed |
| EP-2341911-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | The University of North Carolina At Chapel Hill (US) | 2011-07-13 | — | — | EP | claimed |
| WO-2010039997-A9 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-05-05 | — | — | WO | claimed |
| JP-4524072-B2 | — | — | 2010-08-11 | — | — | JP | claimed |
| WO-2010051127-A2 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-06 | — | — | WO | claimed |
| WO-2010039997-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-04-08 | — | — | WO | claimed |
| WO-2008150260-A1 | 8-OXY-2-AMINOPYRIDO (2, 3-D) PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND ANTICANCER AGENTS | GPC BIOTECH, INC. (US) | 2008-12-11 | — | — | WO | claimed |
| EP-1333833-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-10-24 | — | — | EP | claimed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | claimed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | claimed |
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-01-13 | — | — | US | claimed |
| EP-1470124-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2004-10-27 | — | — | EP | claimed |
| EP-1333833-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | claimed |
| WO-2002059083-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | MAP3K1, MAP3K19, MAP3K20 | IDO1 1511/4885POLB 1696/4885SMN1; SMN2 2902/4885 |
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | IDO1 2549/4885POLB 1768/4885SMN1; SMN2 3156/4885 |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK4, CDK6, CDKN1A | IDO1 2092/4885POLB 1523/4885SMN1; SMN2 4180/4885 |
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | IDO1 2549/4885POLB 1768/4885SMN1; SMN2 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.